A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab

Exclusion criteria

• ✕Medical Conditions
• ✕. Participants with documented allergic fungal rhinosinusitis and/or central compartment atopic disease.
• ✕. Any clinically important pulmonary disease other than asthma (eg, active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc) that could confound interpretation of clinical CRSwNP endpoints results.
• ✕. Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, psychiatric, or major physical impairment that is not stable in the opinion of the investigator and could:
• ✕. Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
• ✕. Participants with conditions or concomitant disease that makes them non-evaluable for the primary CRSwNP endpoints such as:
• ✕. History of cancer:
• ✕. Uncontrolled epistaxis within 2 months of Visit 1.